Literature DB >> 6967856

Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. II. HLA-A- or B-antigen compatibility is not required for HLA-D-region directed cytotoxicity.

C F Feighery, P Stastny.   

Abstract

When effector cells were produced by sensitization in vitro with HLA-A- and B-compatible but HLA-D/DR-incompatible stimulator cells, cytotoxicity apparently was directed against a product of genes closely associated with HLA-D. For effective killing to occur with effector cells against certain minor histocompatibility antigens it is necessary that the effector cells and the target cells be matched for HLA-A or B. We have, therefore, investigated whether sharing of HLA-A or B antigens is needed to obtain efficient lysis with effector cells primed against HLA-D. Good killing was observed with effector cells against HLA-D/DRw3 and against HLA-D/DRw4 whether or not the HLA-A or B antigens were matched. The results indicated that compatibility at HLA-A or B is not required for cell-mediated cytotoxicity against a product of the HLA-D region. The HLA-D region appears to code for products that behave as strong histocompatibility antigens that can by themselves cause cell-mediated killing.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967856     DOI: 10.1007/BF01561551

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  21 in total

1.  Y-antigen killing by T cells of women is restricted by HLA.

Authors:  E Goulmy; A Termijtelen; B A Bradley; J J van Rood
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

2.  HLA-DR antigen matching in cadaver renal transplantation.

Authors:  D Albrechtsen; A Flatmark; J Jervell; B Solheim; E Thorsby
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

3.  Matching for B-cell antigens of the HLA-DR series in cadaver renal transplantation.

Authors:  A Ting; P J Morris
Journal:  Lancet       Date:  1978-03-18       Impact factor: 79.321

4.  Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

Authors:  P Stastny
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

5.  Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. I. Blocking by Unlabelled cells and inhibition by antisera.

Authors:  C F Feighery; P Stastny
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

6.  Matching for HLA antigens of A, B, and DR loci in renal transplantation by Eurotransplant.

Authors:  G G Persijn; B W Gabb; A van Leeuwen; A Nagtegaal; J Hoogeboom; J J van Rood
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

7.  HLA-D region-associated determinants serve as targets for human cell-mediated lysis.

Authors:  C Feighery; P Stastny
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

8.  Histocompatibility antigens controlled by the I region of the murine H-2 complex. II. K/D region compatibility is not required for I-region cell-mediated lymphocytotoxicity.

Authors:  J Klein; C L Chiang; V Hauptfeld
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

9.  Histocompatibility antigens controlled by the I region of the murine H-2 complex. I. Mapping of H-2A and H-2C loci.

Authors:  J Klein; R Geib; C Chiang; V Hauptfeld
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

10.  Induction of cytotoxic T lymphocytes against I-region-coded determinants: in vitro evidence for a third histocompatibility locus in the mouse.

Authors:  H Wagner; D Götze; L Ptschelinzew; M Röllinghoff
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  1 in total

1.  Cell-mediated cytotoxicity against HLA-D-region products expressed in monocytes and B lymphocytes. IV. Characterization of effector cells using monoclonal antibodies against human T-cell subsets.

Authors:  E J Ball; P Stastny
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.